FOLH1 and prostate cancer: Iodine-131(131I)-MIP-1095 is a PSMA-targeted small-molecule inhibitor radionuclide therapy developed by Molecular Insight Pharmaceuticals, Inc. It was one of the first agents used in radiopharmaceutical therapy against prostate cancer.